Journal of Pathology and Translational Medicine

Original Articles

Tumor-infiltrating T lymphocytes evaluated using digital image analysis predict the prognosis of patients with diffuse large B-cell lymphoma: Yunjoo Cho, Jiyeon Lee, Bogyeong Han, Sang Eun Yoon, Seok Jin Kim, Won Seog Kim, Junhun Cho; J Pathol Transl Med. 2024;58(1):12-21. Published online January 10, 2024; DOI: https://doi.org/10.4132/jptm.2023.11.02

1,143 View
175 Download

Abstract PDF: Background
The implication of the presence of tumor-infiltrating T lymphocytes (TIL-T) in diffuse large B-cell lymphoma (DLBCL) is yet to be elucidated. We aimed to investigate the effect of TIL-T levels on the prognosis of patients with DLBCL.
Methods
Ninety-six patients with DLBCL were enrolled in the study. The TIL-T ratio was measured using QuPath, a digital pathology software package. The TIL-T ratio was investigated in three foci (highest, intermediate, and lowest) for each case, resulting in TIL-T–Max, TIL-T–Intermediate, and TIL-T–Min. The relationship between the TIL-T ratios and prognosis was investigated.
Results
When 19% was used as the cutoff value for TIL-T–Max, 72 (75.0%) and 24 (25.0%) patients had high and low TIL-T–Max, respectively. A high TIL-T–Max was significantly associated with lower serum lactate dehydrogenase levels (p < .001), with patient group who achieved complete remission after RCHOP therapy (p < .001), and a low-risk revised International Prognostic Index score (p < .001). Univariate analysis showed that patients with a low TIL-T–Max had a significantly worse prognosis in overall survival compared to those with a high TIL-T–Max (p < .001); this difference remained significant in a multivariate analysis with Cox proportional hazards (hazard ratio, 7.55; 95% confidence interval, 2.54 to 22.42; p < .001).
Conclusions
Patients with DLBCL with a high TIL-T–Max showed significantly better prognosis than those with a low TIL-T–Max, and the TIL-T–Max was an independent indicator of overall survival. These results suggest that evaluating TIL-T ratios using a digital pathology system is useful in predicting the prognosis of patients with DLBCL.

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas: Dina Mohamed El Samman, Manal Mohamed El Mahdy, Hala Sobhy Cousha, Zeinab Abd El Rahman Kamar, Khaled Abdel Karim Mohamed, Hoda Hassan Abou Gabal; J Pathol Transl Med. 2021;55(6):388-397. Published online October 14, 2021; DOI: https://doi.org/10.4132/jptm.2021.08.04

3,030 View
148 Download
3 Web of Science
3 Crossref

Background
Glioblastoma is the most aggressive primary malignant brain tumor in adults and is characterized by poor prognosis. Immune evasion occurs via programmed death-ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) interaction. Some malignant tumors have responded to PD-L1/PD-1 blockade treatment strategies, and PD-L1 has been described as a potential predictive biomarker. This study discussed the expression of PD-L1 and CD8 in glioblastomas.
Methods
Thirty cases of glioblastoma were stained immunohistochemically for PD-L1 and CD8, where PD-L1 expression in glioblastoma tumor tissue above 1% is considered positive and CD-8 is expressed in tumor infiltrating lymphocytes. The expression of each marker was correlated with clinicopathologic parameters. Survival analysis was conducted to correlate progression-free survival (PFS) and overall survival (OS) with PD-L1 and CD8 expression.
Results
Diffuse/fibrillary PD-L1 was expressed in all cases (mean expression, 57.6%), whereas membranous PD-L1 was expressed in six of 30 cases. CD8-positive tumor-infiltrating lymphocytes (CD8⁺ TILs) had a median expression of 10%. PD-L1 and CD8 were positively correlated (p = .001). High PD-L1 expression was associated with worse PFS and OS (p = .026 and p = .001, respectively). Correlation of CD8⁺ TILs percentage with age, sex, tumor site, laterality, and outcomes were statistically insignificant. Multivariate analysis revealed that PD-L1 was the only independent factor that affected prognosis.
Conclusions
PD-L1 expression in patients with glioblastoma is robust; higher PD-L1 expression is associated with lower CD8+ TIL expression and worse prognosis.

Citations

Citations to this article as recorded by

Tumor-associated microenvironment, PD-L1 expression and their relationship with immunotherapy in glioblastoma, IDH-wild type: A comprehensive review with emphasis on the implications for neuropathologists
Giuseppe Broggi, Giuseppe Angelico, Jessica Farina, Giordana Tinnirello, Valeria Barresi, Magda Zanelli, Andrea Palicelli, Francesco Certo, Giuseppe Barbagallo, Gaetano Magro, Rosario Caltabiano
Pathology - Research and Practice.2024; 254: 155144. CrossRef
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
Navid Sobhani, Victoria Bouchè, Giovanni Aldegheri, Andrea Rocca, Alberto D’Angelo, Fabiola Giudici, Cristina Bottin, Carmine Antonio Donofrio, Maurizio Pinamonti, Benvenuto Ferrari, Stefano Panni, Marika Cominetti, Jahard Aliaga, Marco Ungari, Antonio Fi
Biomedicines.2023; 11(2): 311. CrossRef
Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma
Gitanjali Sharma, Marta C. Braga, Chiara Da Pieve, Wojciech Szopa, Tatjana Starzetz, Karl H. Plate, Wojciech Kaspera, Gabriela Kramer-Marek
Cancers.2023; 15(12): 3131. CrossRef

Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters: Gaurav Garg, Kuruswamy Thurai Prasad, Navneet Singh, Parul Gupta, Valliappan Muthu, Ashim Das, Amanjit Bal; J Pathol Transl Med. 2021;55(6):398-405. Published online October 6, 2021; DOI: https://doi.org/10.4132/jptm.2021.08.08

2,724 View
148 Download
2 Web of Science
1 Crossref

Abstract PDF Supplementary Material

Background
Data on the prevalence of programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in non–small cell lung cancer (NSCLC) and their clinical significance in Indian patients are limited.
Methods
Newly diagnosed NSCLC cases (adenocarcinoma or squamous cell carcinoma [SqCC] histology) were included in the present study. The TILs were evaluated based on morphology on hematoxylin and eosin–stained slides. PD-L1 expression in tumors was assessed using immunohistochemistry with rabbit monoclonal antibody (SP263) on the Ventana automated immunostainer. Tumors with PD-L1 expression > 50% on tumor cells were considered PD-L1–positive. Tumors in which TILs occupy > 25% of stroma were considered to have high TILs. The association of PD-L1 expression and TILs with various clinical parameters including overall survival (OS) was investigated.
Results
The present study included 128 cases of NSCLC (67 adenocarcinoma, 61 SqCC). PD-L1 positivity was observed in 17.2% of the patients with NSCLC. Baseline characteristics of PD-L1–positive subjects were similar to PD-L1–negative subjects except for a higher prevalence of liver metastasis (18.2% vs. 2.8%; p = .018) and a higher probability of diagnosis from extrapulmonary biopsies. High TILs were observed in 26.6% of the subjects. However, PD-L1 expression and high TIL did not affect OS.
Conclusions
PD-L1 positivity and high TILs were observed in 20% and 25% of the patients with NSCLC, respectively, however, neither were predictors of survival in SqCC.

Citations

Citations to this article as recorded by

Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study
Prudence A. Russell, Alexandra L. Farrall, Sarita Prabhakaran, Khashayar Asadi, Wade Barrett, Caroline Cooper, Wendy Cooper, Samuel Cotton, Edwina Duhig, Matthew Egan, Stephen Fox, David Godbolt, Shilpa Gupta, Aniza Hassan, Connull Leslie, Trishe Leong, D
Pathology.2023; 55(7): 922. CrossRef

Review

Tumor immune response and immunotherapy in gastric cancer: Yoonjin Kwak, An Na Seo, Hee Eun Lee, Hye Seung Lee; J Pathol Transl Med. 2020;54(1):20-33. Published online November 1, 2019; DOI: https://doi.org/10.4132/jptm.2019.10.08

13,132 View
722 Download
57 Web of Science
52 Crossref

Abstract PDF

Remarkable developments in immuno-oncology have changed the landscape of gastric cancer (GC) treatment. Because immunotherapy intervenes with tumor immune response rather than directly targeting tumor cells, it is important to develop a greater understanding of tumor immunity. This review paper summarizes the tumor immune reaction and immune escape mechanisms while focusing on the role of T cells and their co-inhibitory signals, such as the immune checkpoint molecules programmed death-1 and programmed deathligand 1 (PD-L1). This paper also describes past clinical trials of immunotherapy for patients with GC and details their clinical implications. Strong predictive markers are essential to improve response to immunotherapy. Microsatellite instability, Epstein-Barr virus, PD-L1 expression, and tumor mutational burden are now regarded as potent predictive markers for immunotherapy in patients with GC. Novel immunotherapy and combination therapy targeting new immune checkpoint molecules such as lymphocyte-activation gene 3, T cell immunoglobulin, and mucin domain containing-3, and indoleamine 2,3-dioxygenase have been suggested, and trials are ongoing to evaluate their safety and efficacy. Immunotherapy is an important treatment option for patients with GC and has great potential for improving patient outcome, and further research in immuno-oncology should be carried out.

Citations

Citations to this article as recorded by

Ubiquilin-4 induces immune escape in gastric cancer by activating the notch signaling pathway
Quan Jiang, Hao Chen, Shixin Zhou, Tao Zhu, Wenshuai Liu, Hao Wu, Yong Zhang, Fenglin Liu, Yihong Sun
Cellular Oncology.2024; 47(1): 303. CrossRef
Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells
Lipan Wei, Xiuqian Wu, Lan Wang, Ling Chen, Xuejun Wu, Tiantian Song, Yuanyuan Wang, Wenjun Chang, Aizhen Guo, Yongdong Niu, Haihua Huang
BMC Cancer.2024;[Epub] CrossRef
Identification and characterization of CLEC11A and its derived immune signature in gastric cancer
Qing Zheng, Zhenqi Gong, Baizhi Li, Runzi Cheng, Weican Luo, Cong Huang, Huaiming Wang
Frontiers in Immunology.2024;[Epub] CrossRef
Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer
Hao Yang, Xinyi Gou, Caizhen Feng, Yinli Zhang, Fan Chai, Nan Hong, Yingjiang Ye, Yi Wang, Bo Gao, Jin Cheng
Journal of Translational Medicine.2023;[Epub] CrossRef
A standardized pathology report for gastric cancer: 2nd edition
Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
Journal of Pathology and Translational Medicine.2023; 57(1): 1. CrossRef
A Standardized Pathology Report for Gastric Cancer: 2nd Edition
Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
Journal of Gastric Cancer.2023; 23(1): 107. CrossRef
Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach
Tae-Han Kim, In-Ho Kim, Seung Joo Kang, Miyoung Choi, Baek-Hui Kim, Bang Wool Eom, Bum Jun Kim, Byung-Hoon Min, Chang In Choi, Cheol Min Shin, Chung Hyun Tae, Chung sik Gong, Dong Jin Kim, Arthur Eung-Hyuck Cho, Eun Jeong Gong, Geum Jong Song, Hyeon-Su Im
Journal of Gastric Cancer.2023; 23(1): 3. CrossRef
Could Toll-like Receptor 2 Serve as Biomarker to Detect Advanced Gastric Cancer?
Marek Majewski, Kamil Torres, Paulina Mertowska, Sebastian Mertowski, Izabela Korona-Głowniak, Jan Korulczyk, Witold Zgodziński, Ewelina Grywalska
International Journal of Molecular Sciences.2023; 24(6): 5824. CrossRef
Research Progress of Immunotherapy for Gastric Cancer
Zhipeng Zhang, Ningning Liu, Mingyu Sun
Technology in Cancer Research & Treatment.2023; 22: 153303382211505. CrossRef
Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment
Xinyi Shao, Jin Yin, Di Wang, Erjiong Huang, Yini Zhang, Jiani C. Yin, Chen Huang, Hao Wu, Xiaoli Wu
Frontiers in Oncology.2023;[Epub] CrossRef
Artificial Intelligence-Enabled Gastric Cancer Interpretations
Mustafa Yousif, Liron Pantanowitz
Surgical Pathology Clinics.2023; 16(4): 673. CrossRef
The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer
Jae Yeon Jang, Youngkyung Jeon, Sun Young Jeong, Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim
Journal of Gastric Cancer.2023; 23(3): 476. CrossRef
Biomarkers for Predicting Response to Personalized Immunotherapy in Gastric Cancer
Moonsik Kim, Ji Yun Jeong, An Na Seo
Diagnostics.2023; 13(17): 2782. CrossRef
The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy
Yuting Pan, Yue Ma, Guanghai Dai
Nutrients.2023; 15(19): 4290. CrossRef
Molecular classification of gastric cancer predicts survival in patients undergoing radical gastrectomy based on project HOPE
Kenichiro Furukawa, Keiichi Hatakeyama, Masanori Terashima, Takeshi Nagashima, Kenichi Urakami, Keiichi Ohshima, Akifumi Notsu, Takashi Sugino, Taisuke Yagi, Keiichi Fujiya, Satoshi Kamiya, Makoto Hikage, Yutaka Tanizawa, Etsuro Bando, Yae Kanai, Yasuto A
Gastric Cancer.2022; 25(1): 138. CrossRef
Immunotherapy for gastric cancer: a 2021 update
Christo Kole, Nikolaos Charalampakis, Sergios Tsakatikas, Nikolaos-Iasonas Kouris, George Papaxoinis, Michalis V Karamouzis, Anna Koumarianou, Dimitrios Schizas
Immunotherapy.2022; 14(1): 41. CrossRef
The immune microenvironment in gastric adenocarcinoma
Yana Zavros, Juanita L. Merchant
Nature Reviews Gastroenterology & Hepatology.2022; 19(7): 451. CrossRef
Immunomodulation by Gut Microbiome on Gastrointestinal Cancers: Focusing on Colorectal Cancer
Raghad Khalid AL-Ishaq, Lenka Koklesova, Peter Kubatka, Dietrich Büsselberg
Cancers.2022; 14(9): 2140. CrossRef
An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma
Xiaowen Zhao, Pingfan Wu, Dongling Liu, Changtian Li, Ling Xue, Zhe Liu, Meng Zhu, Jie Yang, Ziyi Chen, Yaling Li, Yali She, Kathiravan Srinivasan
Journal of Healthcare Engineering.2022; 2022: 1. CrossRef
RNA modification writers influence tumor microenvironment in gastric cancer and prospects of targeted drug therapy
Peng Song, Sheng Zhou, Xiaoyang Qi, Yuwen Jiao, Yu Gong, Jie Zhao, Haojun Yang, Zhifen Qian, Jun Qian, Liming Tang
Journal of Bioinformatics and Computational Biology.2022;[Epub] CrossRef
Identification of the three subtypes and the prognostic characteristics of stomach adenocarcinoma: analysis of the hypoxia-related long non-coding RNAs
Zehua Fan, Yanqun Wang, Rong Niu
Functional & Integrative Genomics.2022; 22(5): 919. CrossRef
Complete Response of High Microsatellite Instability Gastric Cancer and Synchronous Microsatellite Stability Rectal Cancer
Zachary E Hunzeker, Pooja Bhakta, Sindusha R Gudipally, Sri Bharathi Kavuri, Rohit Venkatesan, Chukwuyejulumafor Nwanze
Cureus.2022;[Epub] CrossRef
Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression
Yuhan Wei, Jianwei Zhang, Xueke Fan, Zhi Zheng, Xiaoyue Jiang, Dexi Chen, Yuting Lu, Yingrui Li, Miao Wang, Min Hu, Qi Du, Liuting Yang, Hongzhong Li, Yi Xiao, Yongfu Li, Jiangtao Jin, Deying Wang, Xiangliang Yuan, Qin Li
Frontiers in Immunology.2022;[Epub] CrossRef
Tumor vessel normalization and immunotherapy in gastric cancer
Xianzhe Yu, Shan He, Jian Shen, Qiushi Huang, Peng Yang, Lin Huang, Dan Pu, Li Wang, Lu Li, Jinghua Liu, Zelong Liu, Lingling Zhu
Therapeutic Advances in Medical Oncology.2022; 14: 175883592211101. CrossRef
FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers
Han Wang, Junchang Zhang, Huan Li, Hong Yu, Songyao Chen, Shuhao Liu, Changhua Zhang, Yulong He
Frontiers in Oncology.2022;[Epub] CrossRef
Molecular Pathology of Gastric Cancer
Moonsik Kim, An Na Seo
Journal of Gastric Cancer.2022; 22(4): 264. CrossRef
Bioinformatics Analysis and Structure of Gastric Cancer Prognosis Model Based on Lipid Metabolism and Immune Microenvironment
Yongzhi Chen, Hongjun Yuan, Qian Yu, Jianyu Pang, Miaomiao Sheng, Wenru Tang
Genes.2022; 13(9): 1581. CrossRef
Clinical implications of interleukins-31, 32, and 33 in gastric cancer
Qing-Hua Liu, Ji-Wei Zhang, Lei Xia, Steven G Wise, Brett David Hambly, Kun Tao, Shi-San Bao
World Journal of Gastrointestinal Oncology.2022; 14(9): 1808. CrossRef
Microbiota and the Immune System—Actors in the Gastric Cancer Story
Marek Majewski, Paulina Mertowska, Sebastian Mertowski, Konrad Smolak, Ewelina Grywalska, Kamil Torres
Cancers.2022; 14(15): 3832. CrossRef
Bioinformatics and Experimental Analyses Reveal MAP4K4 as a Potential Marker for Gastric Cancer
Junping Zhang, Xiaoping Cai, Weifeng Cui, Zheng Wei
Genes.2022; 13(10): 1786. CrossRef
Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
Shuang Ma, Fei Chen
Pathology - Research and Practice.2022; 238: 154110. CrossRef
High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer
Shouyu Ke, Feng Xie, Yixian Guo, Jieqiong Chen, Zeyu Wang, Yimeng Yu, Haigang Geng, Danhua Xu, Xu Liu, Xiang Xia, Fengrong Yu, Chunchao Zhu, Zizhen Zhang, Gang Zhao, Bin Li, Wenyi Zhao
iScience.2022; 25(12): 105529. CrossRef
Characteristics of Adenosine-to-Inosine RNA editing-based subtypes and novel risk score for the prognosis and drug sensitivity in stomach adenocarcinoma
Jingjing Pan, Xinyuan Gu, Jing Luo, Xinye Qian, Qiang Gao, Tianjie Li, Longying Ye, Chenlu Li
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Inhibition of NF‐κB is required for oleanolic acid to downregulate PD‐L1 by promoting DNA demethylation in gastric cancer cells
Xirong Lu, Yuyi Li, Wei Yang, Minghao Tao, Yanmiao Dai, Jinkang Xu, Qianfei Xu
Journal of Biochemical and Molecular Toxicology.2021;[Epub] CrossRef
Prognostic Value of C-Reactive Protein to Albumin Ratio in Gastric Cancer: A Meta-Analysis
Liang Yue, Yi Lu, Yulin Li, Yilin Wang
Nutrition and Cancer.2021; 73(10): 1864. CrossRef
Immunogenic characteristics of microsatellite instability‐low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses
Yu Imamura, Tasuku Toihata, Ikumi Haraguchi, Yoko Ogata, Manabu Takamatsu, Aya Kuchiba, Norio Tanaka, Osamu Gotoh, Seiichi Mori, Yuichiro Nakashima, Eiji Oki, Masaki Mori, Yoshinao Oda, Kenichi Taguchi, Manabu Yamamoto, Masaru Morita, Naoya Yoshida, Hideo
International Journal of Cancer.2021; 148(5): 1260. CrossRef
Two Similar Signatures for Predicting the Prognosis and Immunotherapy Efficacy of Stomach Adenocarcinoma Patients
Taohua Yue, Shuai Zuo, Jing Zhu, Shihao Guo, Zhihao Huang, Jichang Li, Xin Wang, Yucun Liu, Shanwen Chen, Pengyuan Wang
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Tumor microenvironment characterization in stage IV gastric cancer
Feng Yang, Zhenbao Wang, Xianxue Zhang
Bioscience Reports.2021;[Epub] CrossRef
E2F2 inhibition induces autophagy via the PI3K/Akt/mTOR pathway in gastric cancer
Hui Li, Shufen Zhao, Liwei Shen, Peige Wang, Shihai Liu, Yingji Ma, Zhiwei Liang, Gongjun Wang, Jing Lv, Wensheng Qiu
Aging.2021; 13(10): 13626. CrossRef
Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer
S. H. Petersen, L. F. Kua, S. Nakajima, W. P. Yong, K. Kono
Scientific Reports.2021;[Epub] CrossRef
Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients
Quan Jiang, Jie Sun, Hao Chen, Chen Ding, Zhaoqing Tang, Yuanyuan Ruan, Fenglin Liu, Yihong Sun
Frontiers in Oncology.2021;[Epub] CrossRef
Microsatellite instability in Gastric Cancer: Between lights and shadows
Elisabetta Puliga, Simona Corso, Filippo Pietrantonio, Silvia Giordano
Cancer Treatment Reviews.2021; 95: 102175. CrossRef
Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma
Zai-Sheng Ye, Miao Zheng, Qin-Ying Liu, Yi Zeng, Sheng-Hong Wei, Yi Wang, Zhi-Tao Lin, Chen Shu, Qiu-Hong Zheng, Lu-Chuan Chen
World Journal of Gastroenterology.2021; 27(21): 2871. CrossRef
Immunotherapy of gastric cancer: Past, future perspective and challenges
Jun Xie, Liping Fu, Li Jin
Pathology - Research and Practice.2021; 218: 153322. CrossRef
Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases
Sumi Yun, Sukmook Lee, Ho-Young Lee, Hyeon Jeong Oh, Yoonjin Kwak, Hye Seung Lee
International Journal of Molecular Sciences.2021; 22(13): 7042. CrossRef
Injectable shear-thinning polylysine hydrogels for localized immunotherapy of gastric cancer through repolarization of tumor-associated macrophages
Yan Yang, Yang Yang, Meili Chen, Jianquan Chen, Jinyan Wang, Yajun Ma, Hanqing Qian
Biomaterials Science.2021; 9(19): 6597. CrossRef
Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer
Sizhe Hu, Xiaokang Zhao, Feng Qian, Cancan Jin, Kaishun Hou, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef
Comprehensive Analysis to Identify MAGEA3 Expression Correlated With Immune Infiltrates and Lymph Node Metastasis in Gastric Cancer
Jinji Jin, Jianxin Tu, Jiahuan Ren, Yiqi Cai, Wenjing Chen, Lifang Zhang, Qiyu Zhang, Guanbao Zhu
Frontiers in Oncology.2021;[Epub] CrossRef
Effect of P2X7 receptor on tumorigenesis and its pharmacological properties
Wen-jun Zhang, Ce-gui Hu, Zheng-ming Zhu, Hong-liang Luo
Biomedicine & Pharmacotherapy.2020; 125: 109844. CrossRef
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
Byung Woog Kang, Ian Chau
ESMO Open.2020; 5(4): e000791. CrossRef
Is ramucirumab still the only second-line treatment in metastatic gastric cancer?
Khalil El Gharib, Hampig Raphael Kourie
Pharmacogenomics.2020; 21(17): 1203. CrossRef
Deep Learning Predicts Underlying Features on Pathology Images with Therapeutic Relevance for Breast and Gastric Cancer
Renan Valieris, Lucas Amaro, Cynthia Aparecida Bueno de Toledo Osório, Adriana Passos Bueno, Rafael Andres Rosales Mitrowsky, Dirce Maria Carraro, Diana Noronha Nunes, Emmanuel Dias-Neto, Israel Tojal da Silva
Cancers.2020; 12(12): 3687. CrossRef

Original Articles

Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Miseon Lee, In Ah Park, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee; J Pathol Transl Med. 2019;53(3):180-187. Published online March 11, 2019; DOI: https://doi.org/10.4132/jptm.2019.02.08

6,581 View
197 Download
16 Web of Science
15 Crossref

Abstract PDF

Background
Most triple-negative breast cancers (TNBCs) have a high histologic grade, are associated with high endoplasmic stress, and possess a high frequency of TP53 mutations. TP53 missense mutations lead to the production of mutant p53 protein and usually show high levels of p53 protein expression. Tumor-infiltrating lymphocytes (TILs) accumulate as part of the anti-tumor immune response and have a strong prognostic and predictive significance in TNBC. We aimed to elucidate the association between p53 expression and the amount of TILs in TNBC.
Methods
In 678 TNBC patients, we evaluated TIL levels and expression of endoplasmic stress molecules. Immunohistochemical examination of p53 protein expression was categorized into three groups: no, low, and high expression.
Results
No, low, and high p53 expression was identified in 44.1% (n = 299), 20.1% (n = 136), and 35.8% (n = 243) of patients, respectively. Patients with high p53 expression showed high histologic grade (p < .001), high TIL levels (p = .009), and high expression of endoplasmic reticulum stress-associated molecules (p-eIF2a, p = .013; XBP1, p = .007), compared to patients with low p53 expression. There was no significant difference in disease-free (p = .406) or overall survival rates (p = .444) among the three p53 expression groups.
Conclusions
High p53 expression is associated with increased expression of endoplasmic reticulum stress molecules and TIL influx.

Citations

Citations to this article as recorded by

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
Sotiris Loizides, Anastasia Constantinidou
Frontiers in Genetics.2023;[Epub] CrossRef
Prognostic benefit of TILs independent of clinicopathological and molecular factors
Koen Brummel, Anneke L. Eerkens, Marco de Bruyn, Hans W. Nijman
British Journal of Cancer.2023; 129(5): 737. CrossRef
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Rupert Bartsch, Gabriel Rinnerthaler, Edgar Petru, Daniel Egle, Michael Gnant, Marija Balic, Thamer Sliwa, Christian Singer
Wiener klinische Wochenschrift.2023;[Epub] CrossRef
Dihydroartemisinin-Transferrin Adducts Enhance TRAIL-Induced Apoptosis in Triple-Negative Breast Cancer in a P53-Independent and ROS-Dependent Manner
Xinyu Zhou, Abel Soto-Gamez, Fleur Nijdam, Rita Setroikromo, Wim J. Quax
Frontiers in Oncology.2022;[Epub] CrossRef
New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma
Andrii Puzyrenko, Chandler S Cortina, Julie M Jorns
International Journal of Surgical Pathology.2022; 30(7): 728. CrossRef
Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
Shengnan Sha, Luyi Si, Xinrui Wu, Yuanbiao Chen, Hui Xiong, Ying Xu, Wangrui Liu, Haijun Mei, Tao Wang, Mei Li
Frontiers in Immunology.2022;[Epub] CrossRef
p53 Missense Mutation is Associated with Immune Cell PD-L1 Expression in Triple-Negative Breast Cancer
Ai-Yan Xing, Long Liu, Ke Liang, Bin Wang
Cancer Investigation.2022; 40(10): 879. CrossRef
Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Arpita Poddar, Sushma R. Rao, Prashanth Prithviraj, George Kannourakis, Aparna Jayachandran
Current Oncology.2022; 29(10): 6847. CrossRef
The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
Natsuki Furukawa, Vered Stearns, Cesar A. Santa-Maria, Aleksander S. Popel
Expert Opinion on Therapeutic Targets.2022; 26(12): 1041. CrossRef
Intracellular partners of fibroblast growth factors 1 and 2 - implications for functions
Katarzyna Dominika Sluzalska, Jakub Slawski, Martyna Sochacka, Agata Lampart, Jacek Otlewski, Malgorzata Zakrzewska
Cytokine & Growth Factor Reviews.2021; 57: 93. CrossRef
Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study
Hiu Yee Kwan, Qinghua Xu, Ruihong Gong, Zhaoxiang Bian, Chih-Chang Chu
Frontiers in Oncology.2021;[Epub] CrossRef
Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
Marie Colombe Agahozo, Marcel Smid, Ronald van Marion, Dora Hammerl, Thierry P. P. van den Bosch, Mieke A. M. Timmermans, Chayenne J. Heijerman, Pieter J. Westenend, Reno Debets, John W. M. Martens, Carolien H. M. van Deurzen
Biology.2021; 10(8): 768. CrossRef
With Our Powers Combined
Lawrence Kasherman, Katherine Karakasis, Amit M. Oza
The Cancer Journal.2021; 27(6): 511. CrossRef
The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer

Li Chen, Xiangyi Kong, Chengrui Yan, Yi Fang, Jing Wang
OncoTargets and Therapy.2020; Volume 13: 1397. CrossRef
Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer

Xenia Elena Bacinschi, Anca Zgura, Inga Safta, Rodica Anghel
Cancer Management and Research.2020; Volume 12: 11965. CrossRef

Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer: Hong Sik Park, Uiju Cho, So Young Im, Chang Young Yoo, Ji Han Jung, Young Jin Suh, Hyun Joo Choi; J Pathol Transl Med. 2019;53(2):75-85. Published online November 14, 2018; DOI: https://doi.org/10.4132/jptm.2018.10.11

6,433 View
178 Download
24 Web of Science
27 Crossref

Abstract PDF

Background
Human leukocyte antigen class I (HLA-I) molecules play important roles in regulating immune responses. Loss or reduction of HLA-I expression has been shown to be associated with prognosis in several cancers. Regulatory T-cells (Tregs) also play critical functions in immune response regulation. Evaluation of HLA-I expression status by the EMR8-5 antibody and its clinical impact in breast cancer have not been well studied, and its relationship with Tregs remains unclear.
Methods
We evaluated HLA-I expression and Treg infiltration by immunohistochemistry in 465 surgically resected breast cancer samples. We examined the correlation between HLA-I expression and Treg infiltration and clinicopathologic characteristics and survival analyses were performed.
Results
Total loss of HLA-I expression was found in 84 breast cancer samples (18.1%). Univariate survival analysis revealed that loss of HLA-I expression was significantly associated with worse disease-specific survival (DSS) (p = .029). HLA-I was not an independent prognostic factor in the entire patient group, but it was an adverse independent prognostic factor for DSS in patients with advanced disease (stage II–IV) (p = .031). Treg numbers were significantly higher in the intratumoral stroma of HLA-I–positive tumors than in HLA-I–negative tumors (median 6.3 cells/high power field vs 2.1 cells/high power field, p < .001). However, Tregs were not an independent prognostic factor in our cohort.
Conclusions
Our findings suggest that the loss of HLA-I expression is associated with poor prognosis in breast cancer patients, highlighting the role of HLA-I alterations in immune evasion mechanisms of breast cancer. HLA-I could be a promising marker that enables the application of more effective and precise immunotherapies for patients with advanced breast cancer.

Citations

Citations to this article as recorded by

Comment on “Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta‑Analysis”
Wei Han, Li-zhou Shi, Yu-wei Zhang, Hao-nan Wang
Molecular Diagnosis & Therapy.2024; 28(2): 237. CrossRef
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Daniel S. Lefler, Steven A. Manobianco, Babar Bashir
Cancer Biology & Therapy.2024;[Epub] CrossRef
Cancer Immunology: Immune Escape of Tumors—Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies
Yuan Wang, Simon Jasinski-Bergner, Claudia Wickenhauser, Barbara Seliger
Advances in Anatomic Pathology.2023; 30(3): 148. CrossRef
In Silico Pipeline to Identify Tumor-Specific Antigens for Cancer Immunotherapy Using Exome Sequencing Data
Diego Morazán-Fernández, Javier Mora, Jose Arturo Molina-Mora
Phenomics.2023; 3(2): 130. CrossRef
HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
Ning Jiang, Yue Yu, Dawei Wu, Shuhang Wang, Yuan Fang, Huilei Miao, Peiwen Ma, Huiyao Huang, Min Zhang, Yu Zhang, Yu Tang, Ning Li
Journal of Cancer Research and Clinical Oncology.2023; 149(2): 737. CrossRef
Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance
Sonya Youngju Park, Deog-Gon Cho, Byoung-Yong Shim, Uiju Cho
Diagnostics.2023; 13(6): 1013. CrossRef
Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis
Weiqiang Qiao, Zhiqiang Jia, Wanying Guo, Qipeng Liu, Xiao Guo, Miao Deng
Molecular Diagnosis & Therapy.2023; 27(5): 573. CrossRef
Challenges and solutions for therapeuticTCR‐based agents
Manish Malviya, Zita E. H. Aretz, Zaki Molvi, Jayop Lee, Stephanie Pierre, Patrick Wallisch, Tao Dao, David A. Scheinberg
Immunological Reviews.2023; 320(1): 58. CrossRef
Molecular mechanisms of impaired antigenic presentation as a cause of tumor escape from immune surveillance
A.A. Korotaeva, A.A. Borunova, A.Yu. Kuzevanova, T.N. Zabotina, A.A. Alimov
Arkhiv patologii.2023; 85(6): 76. CrossRef
Immune Escape Mechanism of Cancer
Ayse Caner
Current Molecular Biology Reports.2023; 10(1): 9. CrossRef
Upregulation of MHC I Antigen Processing Machinery Gene Expression in Breast Cancer Cells by Trichostatin A
A. H. Murtadha, N. A. Sharudin, I. I. M. Azahar, A. T. Che Has, N. F. Mokhtar
Molecular Biology.2023; 57(6): 1212. CrossRef
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors
Ananthan Sadagopan, Theodoros Michelakos, Gabriella Boyiadzis, Cristina Ferrone, Soldano Ferrone
JAMA Oncology.2022; 8(3): 462. CrossRef
Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
Brandie C. Taylor, Justin M. Balko
Frontiers in Immunology.2022;[Epub] CrossRef
Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives
Ioannis A. Vathiotis, Ioannis Trontzas, Niki Gavrielatou, Georgia Gomatou, Nikolaos K. Syrigos, Elias A. Kotteas
Clinical Breast Cancer.2022; 22(7): 642. CrossRef
Aberrant synaptophysin expression in classic Hodgkin lymphoma
Soyoung Im, Jeong-A. Kim, Gyeongsin Park, Uiju Cho
Diagnostic Pathology.2022;[Epub] CrossRef
Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer
Song-Hee Han, Milim Kim, Yul Ri Chung, Ji Won Woo, Hye Yeon Choi, So Yeon Park
Scientific Reports.2022;[Epub] CrossRef
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan Wei, Xiao Xiao, Xiang-Ming Lao, Limin Zheng, Dong-Ming Kuang
Cellular and Molecular Life Sciences.2021; 78(3): 867. CrossRef
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara
Journal for ImmunoTherapy of Cancer.2021; 9(8): e002597. CrossRef
Resistance mechanisms to checkpoint inhibitors
Sarah A Weiss, Mario Sznol
Current Opinion in Immunology.2021; 69: 47. CrossRef
The Immunology of Hormone Receptor Positive Breast Cancer
Jonathan Goldberg, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Jennifer L. Guerriero
Frontiers in Immunology.2021;[Epub] CrossRef
B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein
Pu Yu, Lili Zhu, Kang Cui, Yabing Du, Chaojie Zhang, Wang Ma, Jia Guo
Frontiers in Oncology.2021;[Epub] CrossRef
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu, Helen H. Won, Michael F. Berger, Lorenzo Ferrando, Emiliano Cocco, Maud Privat, Flora Ponelle-Chachuat, Catherine Abrial, Jean-Marc Nabholtz, Frederique Penault-Llorca, Jorge S. Reis-Filho, Maurizio Scaltr
npj Breast Cancer.2021;[Epub] CrossRef
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Liam Masterson, James Howard, Jazmina Gonzalez‐Cruz, Christopher Jackson, Catherine Barnett, Lewis Overton, Howard Liu, Rahul Ladwa, Fiona Simpson, Margie McGrath, Ben Wallwork, Terry Jones, Christian Ottensmeier, Melvin L.K. Chua, Chris Perry, Rajiv Khan
International Journal of Cancer.2020; 146(8): 2305. CrossRef
Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers
Julia Y. Tsang, Chun-Sing Ho, Yun-Bi Ni, Yan Shao, Ivan K. Poon, Siu-Ki Chan, Sai-Yin Cheung, Ka-Ho Shea, Monalyn Marabi, Gary M. Tse
Cancer Immunology, Immunotherapy.2020; 69(5): 799. CrossRef
Breast cancer patients overall survival depends on a combination of the polymorphisms of tumor necrosis factor gene and HLA-haplotypes
T.F. Malivanova, E.V. Alferova, A.S. Ostashkin, T.A. Astrelina, N.N. Mazurenko
Molecular Genetics Microbiology and Virology (Russian version).2020; 38(1): 40. CrossRef
The Overall Survival of Breast Cancer Patients Depends on a Combination of Polymorphisms of Tumor Necrosis Factor Gene and HLA Haplotypes
T. F. Malivanova, E. V. Alferova, A. S. Ostashkin, T. A. Astrelina, N. N. Mazurenko
Molecular Genetics, Microbiology and Virology.2020; 35(1): 38. CrossRef
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Fernando Souza-Fonseca-Guimaraes, Joseph Cursons, Nicholas D. Huntington
Trends in Immunology.2019; 40(2): 142. CrossRef

Do Helper T Cell Subtypes in Lymphocytic Thyroiditis Play a Role in the Antitumor Effect?: Seok Woo Yang, Seong-Ho Kang, Kyung Rae Kim, In Hong Choi, Hang Seok Chang, Young Lyun Oh, Soon Won Hong; J Pathol Transl Med. 2016;50(5):377-384. Published online September 15, 2016; DOI: https://doi.org/10.4132/jptm.2016.07.25

7,631 View
107 Download
2 Web of Science
3 Crossref

Abstract PDF

Background
Papillary thyroid carcinoma (PTC) is frequently accompanied by lymphocytic thyroiditis (LT). Some reports claim that Hashimoto’s thyroiditis (the clinical form of LT) enhances the likelihood of PTC; however, others suggest that LT has antitumor activity. This study was aimed to find out the relationship between the patterns of helper T cell (Th) cytokines in thyroid tissue of PTC with or without LT and the clinicopathological manifestation of PTC.
Methods
Fresh surgical samples of PTC with (13 cases) or without (10 cases) LT were used. The prognostic parameters (tumor size, extra-thyroidal extension of PTC, and lymph node metastasis) were analyzed. The mRNA levels of two subtypes of Th cytokines, Th1 (tumor necrosis factor α [TNF-α], interferon γ [IFN-γ ], and interleukin [IL] 2) and Th2 (IL-4 and IL-10), were analyzed. Because most PTC cases were microcarcinomas and recent cases without clinical follow-up, negative or faint p27 immunoreactivity was used as a surrogate marker for lymph node metastasis.
Results
PTC with LT cases showed significantly higher expression of TNF-α (p = .043), IFN-γ (p < .010), IL-4 (p = .015) than those without LT cases. Although the data were not statistically significant, all analyzed cytokines (except for IL-4) were highly expressed in the cases with higher expression of p27 surrogate marker.
Conclusions
These results indicate that mixed Th1 (TNF-α, IFN-γ , and IL-2) and Th2 (IL-10) immunity might play a role in the antitumor effect in terms of lymph node metastasis.

Citations

Citations to this article as recorded by

Obesity and Thyroid Cancer Risk: An Update
Fabiana Franchini, Giuseppe Palatucci, Annamaria Colao, Paola Ungaro, Paolo Emidio Macchia, Immacolata Cristina Nettore
International Journal of Environmental Research and Public Health.2022; 19(3): 1116. CrossRef
Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis
Qizhi Tang, Weiyu Pan, Liangyue Peng, Francis Moore
PLOS ONE.2022; 17(6): e0269995. CrossRef
The Heat Shock Protein Story—From Taking mTORC1,2 and Heat Shock Protein Inhibitors as Therapeutic Measures for Treating Cancers to Development of Cancer Vaccines
Peter Chin Wan Fung, Regina Kit Chee Kong
Journal of Cancer Therapy.2017; 08(11): 962. CrossRef

Review

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer: Sung Gwe Ahn, Joon Jeong, SoonWon Hong, Woo Hee Jung; J Pathol Transl Med. 2015;49(5):355-363. Published online August 17, 2015; DOI: https://doi.org/10.4132/jptm.2015.07.29

12,813 View
227 Download
38 Web of Science
32 Crossref

Abstract PDF

With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-infiltrating lymphocytes (TILs) are emerging as biomarkers mediating tumor response to treatments. Earlier studies have provided evidence that the level of TILs has prognostic value and the potential for predictive value, particularly in triple-negative and human epidermal growth factor receptor 2–positive breast cancer. Moreover, the level of TILs has been associated with treatment outcome in patients undergoing neoadjuvant chemotherapy. To date, no standardized methodology for measuring TILs has been established. In this article, we review current issues and clinical evidence for the use of TILs in breast cancer.

Citations

Citations to this article as recorded by

Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer
Hongyu Gao, Dengjie Ouyang, Xinyu Guan, Jiachi Xu, Qitong Chen, Liyun Zeng, Jian Pang, Qiongyan Zou, Ke Qian, Wenjun Yi
BMC Cancer.2024;[Epub] CrossRef
Precision unveiled: Synergistic genomic landscapes in breast cancer—Integrating single‐cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics
Chenglu Jiang, Shengke Zhang, Lai Jiang, Zipei Chen, Haiqing Chen, Jinbang Huang, Jingyi Tang, Xiufang Luo, Guanhu Yang, Jie Liu, Hao Chi
Environmental Toxicology.2024;[Epub] CrossRef
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non–small cell lung cancer
Uiju Cho, Soyoung Im, Hyung Soon Park
Journal of Pathology and Translational Medicine.2024; 58(2): 49. CrossRef
Predictive and Prognostic Role of Tumor‐Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy
Gaurav Agarwal, K. M. M. Vishvak Chanthar, Shweta Katiyar, Niraj Kumari, Narendra Krishnani, M. Sabaretnam, Gyan Chand, Anjali Mishra, Punita Lal
World Journal of Surgery.2023; 47(5): 1238. CrossRef
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
Ruonan Li, Lili Cao
Frontiers in Immunology.2023;[Epub] CrossRef
Using Self-Assembling ADDomer Platform to Display B and T Epitopes of Type O Foot-and-Mouth Disease Virus
Chaowei Luo, Quanhui Yan, Juncong Huang, Jiameng Liu, Yuwan Li, Keke Wu, Bingke Li, Mingqiu Zhao, Shuangqi Fan, Hongxing Ding, Jinding Chen
Viruses.2022; 14(8): 1810. CrossRef
Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
Guilan Shi, Megan Scott, Cathryn G. Mangiamele, Richard Heller
Pharmaceutics.2022; 14(11): 2429. CrossRef
Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy
Bacinschi Xenia Elena, Laurentia Nicoleta Gales, Anca Florina Zgura, Laura Iliescu, Rodica Maricela Anghel, Bogdan Haineala, Xiaosheng Wang
Journal of Oncology.2021; 2021: 1. CrossRef
Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma
Kyung Un Choi, Ahrong Kim, Jee Yeon Kim, Ki Hyung Kim, Chungsu Hwang, So Jung Lee, Won Young Park, Sejin Jung, Hye Jeong Choi, Kyungbin Kim
Journal of Ovarian Research.2020;[Epub] CrossRef
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review

Weilin Xu, Xiu Chen, Fei Deng, Jian Zhang, Wei Zhang, Jinhai Tang
OncoTargets and Therapy.2020; Volume 13: 5887. CrossRef
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer
Sandra V. Fernandez, Alexander W. MacFarlane, Mowafaq Jillab, Maria F. Arisi, Jennifer Yearley, Lakshmanan Annamalai, Yulan Gong, Kathy Q. Cai, R. Katherine Alpaugh, Massimo Cristofanilli, Kerry S. Campbell
Breast Cancer Research.2020;[Epub] CrossRef
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression
C. Van Berckelaer, C. Rypens, P. van Dam, L. Pouillon, M. Parizel, K. A. Schats, M. Kockx, W. A. A. Tjalma, P. Vermeulen, S. van Laere, F. Bertucci, C. Colpaert, L. Dirix
Breast Cancer Research.2019;[Epub] CrossRef
The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status
Anna Glajcar, Joanna Szpor, Diana Hodorowicz-Zaniewska, Katarzyna Ewa Tyrak, Krzysztof Okoń
Virchows Archiv.2019; 475(1): 13. CrossRef
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
Ana S. Leal, Kayla Zydeck, Sarah Carapellucci, Lyndsey A. Reich, Di Zhang, Jessica A. Moerland, Michael B. Sporn, Karen T. Liby
npj Breast Cancer.2019;[Epub] CrossRef
Stromal tumor‑infiltrating lymphocytes evaluated on H&E‑stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma
Chungsu Hwang, So Lee, Jung Lee, Ki Kim, Dong Suh, Byung‑Su Kwon, Kyung Choi
Oncology Letters.2019;[Epub] CrossRef
The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)
Nobumoto Tomioka, Manabu Azuma, Mayuko Ikarashi, Mitsugu Yamamoto, Masako Sato, Ken-ichi Watanabe, Katsushige Yamashiro, Masato Takahashi
Breast Cancer.2018; 25(1): 34. CrossRef
Triple negative breast cancer – prognostic role of immune-related factors: a systematic review
Elisabeth Specht Stovgaard, Dorte Nielsen, Estrid Hogdall, Eva Balslev
Acta Oncologica.2018; 57(1): 74. CrossRef
Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells
Julian Gomez-Cambronero
Cancer and Metastasis Reviews.2018; 37(2-3): 491. CrossRef
Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
So Jeong Lee, Cheong-Soo Hwang, Young-Keum Kim, Hyun Jung Lee, Sang-Jeong Ahn, Nari Shin, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Chang Hun Lee, Gi Young Huh, Mi Young Sol, Hee Jin Lee, Gyungyub Gong, Jee Yeon Kim, Ahrong Kim
Cancer Research and Treatment.2017; 49(2): 313. CrossRef
Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes
Joo Young Kim, Sun-Hee Heo, Seul Ki Choi, In Hye Song, In Ah Park, Young-Ae Kim, Hye Seon Park, Suk Young Park, Won Seon Bang, Gyungyub Gong, Hee Jin Lee
Virchows Archiv.2017; 470(4): 381. CrossRef
Whole Slide Imaging for Analytical Anatomic Pathology and Telepathology: Practical Applications Today, Promises, and Perils
Alton Brad Farris, Cynthia Cohen, Thomas E. Rogers, Geoffrey H. Smith
Archives of Pathology & Laboratory Medicine.2017; 141(4): 542. CrossRef
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility
Andrea Ravelli, Giandomenico Roviello, Daniele Cretella, Andrea Cavazzoni, Alessandra Biondi, Maria Rosa Cappelletti, Laura Zanotti, Giuseppina Ferrero, Marco Ungari, Fabrizio Zanconati, Alberto Bottini, Roberta Alfieri, Pier Giorgio Petronini, Daniele Ge
Tumor Biology.2017; 39(4): 101042831769502. CrossRef
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
In Hye Song, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, In Ah Park, Young-Ae Kim, Suk Young Park, Jin Roh, Gyungyub Gong, Hee Jin Lee
Cancer Research and Treatment.2017; 49(2): 399. CrossRef
Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?
Weiwei Zhao, Peng Wang, Huixun Jia, Menglei Chen, Xiaoli Gu, Minghui Liu, Zhe Zhang, Wenwu Cheng, Zhenyu Wu
BMC Cancer.2017;[Epub] CrossRef
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Ahrong Kim, So Jeong Lee, Young Keum Kim, Won Young Park, Do Youn Park, Jee Yeon Kim, Chang Hun Lee, Gyungyub Gong, Gi Yeong Huh, Kyung Un Choi
Scientific Reports.2017;[Epub] CrossRef
Negative association between GATA3 and fascin could predict relapse-free and overall survival in patients with breast cancer
Kyueng-Whan Min, Dong-Hoon Kim, Sung-Im Do, Seoung Wan Chae, Kyungeun Kim, Jin Hee Sohn, Jung-Soo Pyo, Hyun Joo Lee, Dong Hyun Kim, Sukjoong Oh, Seon Hyeong Choi, Yong Lai Park, Chan Heun Park, Eun-Kyung Kim, Mi Jung Kwon, Jinwon Seo, Kyoung Min Moon
Virchows Archiv.2016; 468(4): 409. CrossRef
Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor‐infiltrating lymphocytes (TILs) in breast cancer
Hee Jin Lee, Ahrong Kim, In Hye Song, In Ah Park, Jong Han Yu, Jin Hee Ahn, Gyungyub Gong
Pathology International.2016; 66(4): 202. CrossRef
Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
Kyu-pyo Kim, Hun Jung
Translational and Clinical Pharmacology.2016; 24(1): 7. CrossRef
The next level of 3D tumour models: immunocompetence
Agata Nyga, Joana Neves, Katerina Stamati, Marilena Loizidou, Mark Emberton, Umber Cheema
Drug Discovery Today.2016; 21(9): 1421. CrossRef
An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes
Ahrong Kim, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee
American Journal of Clinical Pathology.2016; 146(1): 137. CrossRef
High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer
Kyueng-Whan Min, Dong-Hoon Kim, Sung-Im Do, Jung-Soo Pyo, Seoung Wan Chae, Jin Hee Sohn, Kyungeun Kim, Hyun Joo Lee, Dong Hyun Kim, Sukjoong Oh, Seon Hyeong Choi, Yong Lai Park, Chan Heun Park, Mi Jung Kwon, Kyoung Min Moon
Postgraduate Medical Journal.2016; 92(1094): 707. CrossRef
Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Changro Lee, Seho Park, Joo Heung Kim, Sung Mook Lim, Hyung Seok Park, Seung Il Kim, Byeong-Woo Park
Journal of Breast Cancer.2016; 19(4): 385. CrossRef

Original Articles

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma: Su-Jin Shin, Jin Roh, Misung Kim, Min Jung Jung, Young Wha Koh, Chan-Sik Park, Dok Hyun Yoon, Cheolwon Suh, Chan-Jeong Park, Hyun Sook Chi, Jooryung Huh; Korean J Pathol. 2013;47(6):526-533. Published online December 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.6.526

10,677 View
66 Download
24 Crossref

Abstract PDF

Background

Absolute lymphocyte count (ALC) in peripheral blood has recently been reported to be an independent prognostic factor in multiple myeloma (MM). Previous studies indicated that the absolute monocyte count (AMC) in peripheral blood reflects the state of the tumor microenvironment in lymphomas. Neither the utility of the AMC nor its relationship with ALC has been studied in MM.

Methods

The prognostic value of ALC, AMC, and the ALC/AMC ratio at the time of diagnosis was retrospectively examined in 189 patients with MM.

Results

On univariate analysis, low ALC (<1,400 cells/µL), high AMC (≥490 cells/µL), and low ALC/AMC ratio (<2.9) were correlated with worse overall survival (OS) (p=.002, p=.038, and p=.001, respectively). On multivariate analysis, the ALC/AMC ratio was an independent prognostic factor (p=.047), whereas ALC and AMC were no longer statistical significant. Low ALC, high AMC, and low ALC/AMC ratio were associated with poor prognostic factors such as high International Staging System stage, plasmablastic morphology, hypoalbuminemia, and high β2-microglobulin.

Conclusions

Univariate analysis demonstrated that changes in ALC, AMC, and the ALC/AMC ratio are associated with patient survival in MM. Multivariate analysis showed that, of these factors, the ALC/AMC ratio was an independent prognostic factor for OS.

Citations

Citations to this article as recorded by

Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer
Xiaoming Wang, Dayu Chen, Yuyan Ma, Dongping Mo, Feng Yan
Clinical and Translational Oncology.2024;[Epub] CrossRef
Descriptive analysis and prognostic factors in cats with myeloma‐related disorders: A multicenter retrospective study of 50 cases
Lorris Lecot, Isabelle Desmas‐Bazelle, Sarah Benjamin, Pauline De Fornel, Frédérique Ponce, Matthew Kornya, Loïc Desquilbet, Claire Beaudu‐Lange, Catherine Ibisch, David Sayag, Ghita Benchekroun, Jérémy Béguin
Journal of Veterinary Internal Medicine.2024;[Epub] CrossRef
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling
Rahul Banerjee, Kara I. Cicero, Sarah S. Lee, Andrew J. Cowan
Frontiers in Oncology.2023;[Epub] CrossRef
Normal Absolute Monocyte Count in Combination with Normal/High Absolute Lymphocyte Count at the Time of Relapse is Associated with Improved Survival in Patients with Early Relapsed Acute Myeloid Leukemia
Yu Zhang, Kanchun Dai, Qianying Zhang, Yisha Huang, Yiyun Feng, Deeksha Bhardwaj, Kang Yu, Jianhua Feng
Cancer Investigation.2021; 39(6-7): 550. CrossRef
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
Francesca Cottini, Ying Huang, Nita Williams, Naresh Bumma, Abdullah M. Khan, Maria Chaudhry, Srinivas Devarakonda, Yvonne A. Efebera, Don M. Benson, Ashley E. Rosko
Frontiers in Oncology.2021;[Epub] CrossRef
Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis
Xinwen Zhang, Jialin Duan, Zhenyu Wen, Hao Xiong, Xiaomin Chen, Yang Liu, Kunyu Liao, Chunlan Huang
Frontiers in Oncology.2021;[Epub] CrossRef
Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant
Karen Sweiss, Jonathan Lee, Nadim Mahmud, Gregory S. Calip, Youngmin Park, Dolores Mahmud, Damiano Rondelli, Pritesh R. Patel
Bone Marrow Transplantation.2020; 55(1): 199. CrossRef
Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma
Yan Gu, Yuanyuan Jin, Jie Ding, Wu Yujie, Qinglin Shi, Xiaoyan Qu, Sishu Zhao, Jianyong Li, Chen Lijuan
Leukemia & Lymphoma.2020; 61(8): 1869. CrossRef
Normal Absolute Monocyte Count at the Time of Relapse is Associated with Improved Survival After First Salvage Therapy in Adult Patients with Early Relapsed B-Lineage Acute Lymphoblastic Leukemia

Yi-fen Shi, Na Wang, Zi-yang Huang, Rong-rong Chen, Yi-sha Huang, Yi-yi Zhu, Chong-yun Xing, Bin Liang, Kang Yu, Jian-hua Feng
Cancer Management and Research.2020; Volume 12: 7097. CrossRef
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma
Moritz Binder, S. Vincent Rajkumar, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Angela Dispenzieri, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Suzanne R. Hayman, Steven R. Zeldenrust, John A. Lust, Stephen J. Russell, Nelson Leung, Prashant Kapoor, Ronal
American Journal of Hematology.2019; 94(3): 306. CrossRef
Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning
Liyuan Tang, Na Wang, Chongyun Xing, Qiang Zhuang, Bin Liang, Lan Sun, Yi Chen, Yan Qian, Zhijian Shen, Songfu Jiang, Kang Yu, Jianhua Feng
Leukemia Research.2018; 69: 60. CrossRef
A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified
Qian Li, Shuang Gao, Jing Ma, Su Liu, Yuanfang Yue, Lin Chen, Han Li, Xue Wang, Dongying Li, Zeng Cao, Zhigang Zhao, Xiaofang Wang, Yong Yu, Yizhuo Zhang, Yafei Wang
Leukemia Research.2018; 73: 5. CrossRef
Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
Ying Tian, Yue Zhang, Wan-Qiu Zhu, Xiao-Lei Chen, He-Bing Zhou, Wen-Ming Chen
BioMed Research International.2018; 2018: 1. CrossRef
Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
T Dosani, F Covut, R Beck, J J Driscoll, M de Lima, E Malek
Blood Cancer Journal.2017; 7(6): e579. CrossRef
Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma
Gurshawn Singh, Ammar Nassri, David Kim, Hong Zhu, Zeeshan Ramzan
World Journal of Gastrointestinal Pharmacology and Therapeutics.2017; 8(1): 60. CrossRef
Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma – an analysis from the Austrian Myeloma Registry
Wolfgang Willenbacher, Ella Willenbacher, Claudia Zelle-Rieser, Rainer Biedermann, Roman Weger, Karin Jöhrer, Andrea Brunner
Leukemia & Lymphoma.2016; 57(6): 1478. CrossRef
Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients
C. Suriu, L. Akria, D. Azoulay, E. Shaoul, M. Barhoum, A. Braester
International Journal of Laboratory Hematology.2016;[Epub] CrossRef
The Peripheral Blood Mononuclear Cell Count Is Associated With Bone Health in Elderly Men
Xianfeng Lin, Hejun Yu, Chenchen Zhao, Yu Qian, Dun Hong, Kangmao Huang, Jian Mo, An Qin, Xiangqian Fang, Shunwu Fan
Medicine.2016; 95(15): e3357. CrossRef
Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis
Liangyou Gu, Hongzhao Li, Luyao Chen, Xin Ma, Xintao Li, Yu Gao, Yu Zhang, Yongpeng Xie, Xu Zhang
Oncotarget.2016; 7(22): 31926. CrossRef
Do lymphocytes count in myeloma? Are we absolutely sure?
Tamar Tadmor
Leukemia & Lymphoma.2015; 56(5): 1193. CrossRef
Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs
Mariasanta Napolitano, Giorgia Saccullo, Roberto Bono, Antonio Branca, Clotilde Cangialosi, Salvatrice Mancuso, Simona Raso, Gerlando Quintini, Maria Grazia Lipari, Francesco Fabbiano, Giorgina Specchia, Alberto Dolce, Francesco Di Raimondo, Sergio Siragu
Leukemia & Lymphoma.2015; 56(5): 1507. CrossRef
Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes
Vivek Naranbhai, Helen A. Fletcher, Rachel Tanner, Matthew K. O'Shea, Helen McShane, Benjamin P. Fairfax, Julian C. Knight, Adrian V.S. Hill
EBioMedicine.2015; 2(11): 1619. CrossRef
Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia
László Szerafin, János Jakó, Ferenc Riskó
Orvosi Hetilap.2015; 156(15): 592. CrossRef
The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer
Michael Stotz, Joanna Szkandera, Tatjana Stojakovic, Julia Seidel, Hellmut Samonigg, Peter Kornprat, Renate Schaberl-Moser, Fridericke Seggewies, Gerald Hoefler, Armin Gerger, Martin Pichler
Clinical Chemistry and Laboratory Medicine (CCLM).2015;[Epub] CrossRef

Progressive Increase of Regulatory T Cells and Decrease of CD8+ T Cells and CD8+ T Cells/Regulatory T Cells Ratio during Colorectal Cancer Development: Tae Jung Jang; Korean J Pathol. 2013;47(5):443-451. Published online October 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.5.443

7,813 View
52 Download
24 Crossref

Abstract PDF

Background

We examined the distribution of CD8+ T cells and regulatory T cells (Tregs), measured the CD8+ T cell/Tregs ratio, investigated the relationship between Tregs and cyclooxygenase-2 (COX-2) expression during colorectal cancer (CRC) development.

Methods

We performed immunohistochemical staining for CD8, forkhead box P3, E-cadherin, and COX-2 in 32 cases of invasive CRC, 10 cases of intramucosal CRC, 27 cases of high-grade tubular adenoma, 22 cases of low-grade tubular adenoma, and 32 cases of non-neoplastic conditions.

Results

We observed a progressive increase in Tregs, and a decrease in CD8+ T cells and the CD8+ T cells/Tregs ratio during CRC development. The alterations were most severe in high-grade tubular adenoma and CRC. COX-2 expression was positively associated with Tregs infiltration. The degree of T cell infiltration differed among tumor compartment and the ratio in the tumor center was the lowest of all areas. The ratio and number of CD8+ T cells in the tumor center and the invasive front of invasive CRC were associated with gender, differentiation, node metastasis and tumor budding.

Conclusions

Alteration in the distribution of both CD8+T cells and Tregs may contribute to the generation of an immune environment suitable for the development and progression of CRC.

Citations

Citations to this article as recorded by

Tumor Microenvironment and Immune Response in Lip Cancer
Anastasia G. Gkegka, Michael I. Koukourakis, Maria Lambropoulou, Alexandra Giatromanolaki
Cancers.2023; 15(5): 1478. CrossRef
Regenerating gene 4 promotes chemoresistance of colorectal cancer by affecting lipid droplet synthesis and assembly
Cong-Yu Zhang, Rui Zhang, Li Zhang, Zi-Mo Wang, Hong-Zhi Sun, Zheng-Guo Cui, Hua-Chuan Zheng
World Journal of Gastroenterology.2023; 29(35): 5104. CrossRef
Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer
Phimmada Hatthakarnkul, Jean A. Quinn, Aula Ammar, Gerard Lynch, Hester Van Wyk, Donald C. McMillan, Chanitra Thuwajit, Joanne Edwards
Clinical Science.2022; 136(8): 521. CrossRef
Attackers and defenders: tumor buds and lymphocytes as morphological biomarkers in colorectal cancer
Sonay Kus Öztürk, Tariq S. Haddad, Inti Zlobec, Alessandro Lugli, Iris D. Nagtegaal
Diagnostic Histopathology.2022; 28(11): 480. CrossRef
The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes
Xiaoying Sun, Lili Liu, Ting Wan, Qidan Huang, Jieping Chen, Rongzhen Luo, Jihong Liu
Cancer Cell International.2022;[Epub] CrossRef
Preinvasive Colorectal Lesions of African Americans Display an Immunosuppressive Signature Compared to Caucasian Americans
Kristin Wallace, Georges J. Nahhas, Christine Bookhout, David N. Lewin, Chrystal M. Paulos, Nana Nikolaishvili-Feinberg, Stephanie M. Cohen, Silvia Guglietta, Ali Bakhtiari, E. Ramsay Camp, Elizabeth G. Hill, John A. Baron, Jennifer D. Wu, Alexander V. Al
Frontiers in Oncology.2021;[Epub] CrossRef
Cancer Immunoprevention: Current Status and Future Directions
Mahsa Keshavarz-Fathi, Nima Rezaei
Archivum Immunologiae et Therapiae Experimentalis.2021;[Epub] CrossRef
Transcriptomic Analyses of the Adenoma-Carcinoma Sequence Identify Hallmarks Associated With the Onset of Colorectal Cancer
Qin Hong, Bing Li, Xiumei Cai, Zhengtao Lv, Shilun Cai, Yunshi Zhong, Bo Wen
Frontiers in Oncology.2021;[Epub] CrossRef
Immune Responses Vary in Preinvasive Colorectal Lesions by Tumor Location and Histology
Kristin Wallace, Georges J. El Nahas, Christine Bookhout, Jessica E. Thaxton, David N. Lewin, Nana Nikolaishvili-Feinberg, Stephanie M. Cohen, J. Grant Brazeal, Elizabeth G. Hill, Jennifer D. Wu, John A. Baron, Alexander V. Alekseyenko
Cancer Prevention Research.2021; 14(9): 885. CrossRef
CD103+ T Lymphocyte Count Linked to the Thickness of Invasion on Acral Melanoma without E-Cadherin Involvement
Fauzan Ali Zainal Abidin, Hermin Aminah Usman, Sri Suryanti, Bethy S Hernowo
Clinical, Cosmetic and Investigational Dermatology.2021; Volume 14: 1783. CrossRef
FOXP3 and CD25 double staining antibody cocktails identify regulatory T cells in different types of tumor tissues using tissue microarrays
Xinmin Liu, Xiaohong Wang, Jianmin Ding, Yan Gao, Yiming Zhao, Ruihua Zhao, Qigang Sun, Songlin Zhang
Annals of Diagnostic Pathology.2019; 38: 67. CrossRef
Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells
Chiara Marchiori, Melania Scarpa, Andromachi Kotsafti, Susan Morgan, Matteo Fassan, Vincenza Guzzardo, Andrea Porzionato, Imerio Angriman, Cesare Ruffolo, Stefania Sut, Stefano Dall’Acqua, Romeo Bardini, Raffaele De Caro, Carlo Castoro, Marco Scarpa, Igna
Journal of Experimental & Clinical Cancer Research.2019;[Epub] CrossRef
Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer
Ines P. Nearchou, Kate Lillard, Christos G. Gavriel, Hideki Ueno, David J. Harrison, Peter D. Caie
Cancer Immunology Research.2019; 7(4): 609. CrossRef
Colorectal cancer prevention: Immune modulation taking the stage
Rochelle Fletcher, Yi-Jun Wang, Robert E. Schoen, Olivera J. Finn, Jian Yu, Lin Zhang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2018; 1869(2): 138. CrossRef
The Major Role of NF-κB in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells
Hermin Aminah Usman, Bethy S. Hernowo, Maringan Diapari Lumban Tobing, Reti Hindritiani
Journal of Pathology and Translational Medicine.2018; 52(3): 164. CrossRef
Increased number of arginase 1-positive cells in the stroma of carcinomas compared to precursor lesions and nonneoplastic tissues
Tae Jung Jang, Sun A. Kim, Min Kyung Kim
Pathology - Research and Practice.2018; 214(8): 1179. CrossRef
Hematopoietic stem cell specific V-ATPase controls breast cancer progression and metastasis via cytotoxic T cells
Manoranjan Sahoo, Gajendra K. Katara, Mahmood Y. Bilal, Safaa A. Ibrahim, Arpita Kulshrestha, Sara Fleetwood, Kimiko Suzue, Kenneth D. Beaman
Oncotarget.2018; 9(69): 33215. CrossRef
Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis
Robert E. Brown, Robert L. Hunter, Shen-An Hwang
Frontiers in Immunology.2017;[Epub] CrossRef
O-GlcNAcylation is associated with the development and progression of gastric carcinoma
Tae Jung Jang, Ui Jung Kim
Pathology - Research and Practice.2016; 212(7): 622. CrossRef
The Immune Landscapes of Polypoid and Nonpolypoid Precancerous Colorectal Lesions
Antonella Maglietta, Rosalia Maglietta, Teresa Staiano, Ramona Bertoni, Nicola Ancona, Giancarlo Marra, Leonardo Resta, Hiroshi Shiku
PLOS ONE.2016; 11(7): e0159373. CrossRef
Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment
Shuping Zhang, Xing Ke, Suyun Zeng, Meng Wu, Jianfang Lou, Lei Wu, Peijun Huang, Lei Huang, Fang Wang, Shiyang Pan
Cellular & Molecular Immunology.2015; 12(5): 580. CrossRef
The Distribution of CD8- and Foxp3-positive T Cells in Skin Squamous Cell Tumors and Basal Cell Carcinomas
Tae Jung Jang
Journal of Life Science.2015; 25(6): 686. CrossRef
Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer
Jingying Hou, Zhong Yu, Rengyun Xiang, Chuqiang Li, Lin Wang, Shufen Chen, Qingyun Li, Mei Chen, Linyun Wang
Experimental and Molecular Pathology.2014; 96(3): 284. CrossRef
Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs)
Qiushi Wang, Xinghua Gao, Zhe Yuan, Zhe Wang, Yiming Meng, Yan Cao, Nicolas P Plotnikoff, Noreen Griffin, Fengping Shan
Human Vaccines & Immunotherapeutics.2014; 10(7): 1836. CrossRef

Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer.: Hanna Kang, Harin Cheong, Min Sun Cho, Heasoo Koo, Woon Sup Han, Kyung Eun Lee, Byung In Moon, Sun Hee Sung; Korean J Pathol. 2011;45(1):53-61.; DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.1.53

4,634 View
66 Download
2 Crossref

Abstract PDF

BACKGROUND
Triple negative breast cancer (TNBC) is defined as a lack of the expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer. Many TNBCs show a profound infiltration of tumor infiltrating lymphocytes (TILs). It is still uncertain whether these TILs are protumoral or antitumoral. Regulatory T cells (Tregs) play a role in inducing immune tolerance to antigens, and they may be selectively recruited by cancer cells. This study was conducted to evaluate the significance of TILs with an emphasis on forkhead box p3 (Foxp3), which is a marker for CD25+CD4+ Treg in TNBC.
METHODS
We investigated the Foxp3, CD8 and CD4 expressions in 100 cases of TNBC by immunohistochemistry and using a tissue microarray. The Foxp3 expression was divided as the high and low infiltration groups (cut-off value=20).
RESULTS
The high infiltration group was correlated with higher histologic and nuclear grades. However, Foxp3+ Tregs were decreased in the T3 and T4 TNBCs as compared to that of the T1 and T2 TNBCs. No significant differences were found for the nodal status, lymphovascular invasion, stage, recurrence and overall survival.
CONCLUSIONS
High Foxp3+ Treg infiltration in TNBC is correlated with the nuclear and histologic grades, but there was no relation to recurrence and overall survival.

Citations

Citations to this article as recorded by

Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
In Hye Song, Sun-Hee Heo, Won Seon Bang, Hye Seon Park, In Ah Park, Young-Ae Kim, Suk Young Park, Jin Roh, Gyungyub Gong, Hee Jin Lee
Cancer Research and Treatment.2017; 49(2): 399. CrossRef
Zonal Difference and Prognostic Significance of Foxp3 Regulatory T Cell Infiltration in Breast Cancer
Sewha Kim, Anbok Lee, Woosung Lim, Sanghui Park, Min Sun Cho, Heasoo Koo, Byung-In Moon, Sun Hee Sung
Journal of Breast Cancer.2014; 17(1): 8. CrossRef

Distribution of Dendritic Cells and Regulatory T-Cells in Cutaneous Lymphomas.: Changyoung Yoo, Young Seon Hong, Baik Kee Cho, Sang Ho Kim, Sang In Shim, Chang Suk Kang; Korean J Pathol. 2010;44(6):581-588.; DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.6.581

2,828 View
17 Download

Abstract PDF: BACKGROUND
Dendritic cells (DCs) play an important role in immune reactions. This study was designed to identify the distribution patterns of DCs and regulatory T-cells (Tregs) in cutaneous lymphomas.
METHODS
Immunohistochemistry was used to determine langerin expression on Langerhans cells, CD11b on inflammatory DCs, CD209 and CD11c on dermal DCs, CD303 on plasmacytic DCs, and Foxp3 on Tregs in 81 cases of cutaneous lymphomas.
RESULTS
Various DCs and Tregs were identified in most cutaneous lymphomas. Plasmacytic DCs, inflammatory DCs and Tregs were identified mainly in tumor areas, whereas dermal DCs were distributed both in the tumor and stromal areas. Among DCs, dermal DCs were most prominently identified in the cutaneous lymphomas not only in the tumor area but also in the stroma. The intense stromal infiltration of dermal DCs was consistent finding in T-cell lymphomas. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified also showed intense stromal infiltration of dermal DCs, but stromal infiltration in DLBCL, leg type was relatively scant.
CONCLUSIONS
The results suggest that all types of DCs and Tregs are involved in cutaneous lymphoma tumor immunity. Among them dermal DCs may play a dominant role.

Frequency of Intrahepatic FoxP3+ Regulatory T cells during the Natural Course of Chronic Hepatitis B: An Immunohistochemical Study Using Needle-Biopsied Liver Tissue.: Ji Yoon Bae, Hyung Kyung Kim, Hanna Kang, Ha Rin Cheong, Dong Eun Song, Sun Hee Sung, Heasoo Koo, Woon Sup Han, Jeong Kyong Lee, Tae Hun Kim, Kyu Won Chung, Min Sun Cho; Korean J Pathol. 2010;44(2):132-140.; DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.2.132

3,149 View
24 Download
1 Crossref

Abstract PDF

BACKGROUND
Regulatory T cells (Tregs) may contribute to the immunological hyporesponsiveness against hepatitis B virus (HBV), and this can result in chronic infection. Tregs suppress the T cell responses directed against HBV and they protect hepatocytes by down-regulating the immune responses that cause liver damage, but the role of Tregs has not been well characterized.
METHODS
Fifty four patients were selected and classified into three groups (12 were in the immune-tolerance phase, 35 were in the immune-clearance phase and 7 were in the asymptomatic virus carrier phase). We examined the frequency of CD3+, CD4+ & CD8+ T cells and forkhead box P3 (FoxP3)+ Tregs in the needle-biopsied liver tissue by performing immunohistochemistry.
RESULTS
The FoxP3+ Tregs were mainly located at the portal tracts. In the immune-clearance phase, the frequency of FoxP3+ Tregs was significantly increased compared to that of the immune-tolerance group and the asymptomatic carrier group. Increased FoxP3+ T cells were observed in the patients with a higher histologic inflammatory index. No correlation was observed among the numbers of FoxP3+ Tregs, the serum alanine aminotransferase level, detection of HBeAg and the HBV-DNA viral load.
CONCLUSIONS
FoxP3+ Tregs may play important roles in suppressing the immune response to HBV and the complete elimination of HBV.

Citations

Citations to this article as recorded by

Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer
Hanna Kang, Harin Cheong, Min Sun Cho, Heasoo Koo, Woon Sup Han, Kyung Eun Lee, Byung In Moon, Sun Hee Sung
The Korean Journal of Pathology.2011; 45(1): 53. CrossRef

The Prognostic Significance of the Tumor-Infiltrating FoxP3-Positive Regulatory T Cells in Gastric Carcinoma.: Sang Jae Noh, Shin Young Park, Kyung Ryoul Kim, Chan Young Kim, Keun Sang Kwon, Ho Sung Park, Ho Lee, Myoung Ja Chung, Woo Sung Moon, Kyu Yun Jang; Korean J Pathol. 2010;44(1):9-15.; DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.1.9

3,366 View
31 Download
2 Crossref

Abstract PDF

BACKGROUND
Regulatory T cells (Tregs) are known to be key regulators of immune responses in patients with autoimmune disease and infection and also for attenuating antitumor immunity by the host. It has been reported that high numbers of tumor-infiltrating Tregs might be associated with poor clinical outcomes for several malignant tumors. Therefore, this study aimed to examine the impact of tumor-infiltrating Tregs on the prognosis of gastric carcinoma patients.
METHODS
The immunohistochemical staining for anti-fork head Box P3 (FoxP3) antibody was performed by using a 3 mm core from the tumor specimens of each of the 173 gastric cancer patients for constructing a tissue microarray. FoxP3-positive Tregs were quantified by calculating the numbers of positive cells per 5 high-power fields on light microscopy. Thereafter, the 173 patients were subdivided into the low Tregs group (< or = 3/5 high power fields [HPF], n = 41) and the high Tregs group (> 3/5 HPF, n = 132).
RESULTS
The high Tregs group was significantly associated with a higher stage, more invasion depth and lymph node metastasis (p = 0.009, p = 0.036, p = 0.006, respectively). The high Tregs group showed significantly poorer overall survival and event-free survival (p = 0.004, p = 0.017, respectively) on the univariate analysis. The Tregs group and the tumor, node and metastasis stage were also independent prognostic factors that were significantly associated with overall survival (p = 0.025, p < 0.001, respectively) by multivariate analysis.
CONCLUSIONS
Our results indicated that a high number of tumor-infiltrating FoxP3-positive Tregs could be an indicator of poor long term survival for gastric carcinoma patients.

Citations

Citations to this article as recorded by

Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma
Myoung Jae Kang, Kyoung Min Kim, Jun Sang Bae, Ho Sung Park, Ho Lee, Myoung Ja Chung, Woo Sung Moon, Dong Geun Lee, Kyu Yun Jang
Translational Oncology.2013; 6(3): 282. CrossRef
Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer
Hanna Kang, Harin Cheong, Min Sun Cho, Heasoo Koo, Woon Sup Han, Kyung Eun Lee, Byung In Moon, Sun Hee Sung
The Korean Journal of Pathology.2011; 45(1): 53. CrossRef

DNA Methylation Profiles of MGMT, DAPK1, hMLH1, CDH1, SHP1, and HIC1 in B-Cell Lymphomas.: Sung Sun Kim, Young Hyo Choi, Chang Woo Han, Yoo Duk Choi, Youngkyu Park, Je Jung Lee, Hyeoung Joon Kim, Il Kwon Lee, Ji Shin Lee, Sang Woo Juhng, Chan Choi; Korean J Pathol. 2009;43(5):420-427.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.5.420

3,506 View
31 Download
2 Crossref

Abstract PDF

BACKGROUND
This study was designed to examine the prevalence of aberrant promoter methylation in a selected panel of genes potentially involved in lymphoid tumors.
METHODS
The promoter hypermethylation status of MGMT, DAPK1, hMLH1, CDH1, SHP1, and HIC1 was measured by methylation-specific PCR for 82 cases of B-cell lymphoma. Immunohistochemical staining using MGMT and SHP1 antibodies was conducted on 43 out of 82 cases.
RESULTS
The number of MGMT aberrant methylations was lower in diffuse large B-cell lymphoma (DLBCL) than in other malignant lymphomas. The methylation of DAPK1 was frequently detected in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and DLBCL. With one exception, methylation of hMLH1 was not observed in B-cell lymphomas. The methylation frequency of CDH1, and HIC1 was similar in B-cell lymphomas. However, the methylation of SHP1 gene was more frequently observed in cases of FL, DLBCL, and MZL than in chronic lymphocytic lymphoma. MGMT and SHP1 promoter methylation were inversely correlated with the protein expression observed upon immunohistochemical staining.
CONCLUSIONS
Aberrant promoter methylation of multiple genes occurs with variable frequency throughout the B-cell lymphomas, and methylation of hMLH1 is rarely observed in B-cell lymphomas.

Citations

Citations to this article as recorded by

Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma
Kai Ding, Xiaoshuang Chen, Yihao Wang, Hui Liu, Wenjing Song, Lijuan Li, Guojin Wang, Jia Song, Zonghong Shao, Rong Fu
International Journal of Clinical Oncology.2017; 22(3): 585. CrossRef
Hypermethylation of p15 Gene in Diffuse – Large B‐Cell Lymphoma: Association with Less Aggressiveness of the Disease
Milena Krajnović, Maja Peruničić Jovanović, Biljana Mihaljević, Boško Anđelić, Olivera Tarabar, Slavica Knežević‐Ušaj, Koviljka Krtolica
Clinical and Translational Science.2014; 7(5): 384. CrossRef

First
Prev
Page of 2
Next
Last

Search